# A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

> **NCT03752970** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 27 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03752970
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-05
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-07-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752970, "A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03752970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*